SEED Therapeutics Appoints Bill Desmarais as CFO & CBO
Slice of Healthcare Team
06/11/2025
Key highlights
- SEED appoints Bill Desmarais, Ph.D., MBA, as Chief Financial Officer & Chief Business Officer
- Desmarais brings 20+ years of leadership in biotech finance & business development
- SEED advances clinical pipeline & expands global strategic partnerships
- Company’s RITE3™ platform targets oncology, neurodegeneration, and immunology
- Lead RBM39 degrader program to enter clinical trials in 2025
Notable Quotes
“ Bill’s appointment comes at a pivotal time as SEED advances its differentiated pipeline into clinical trials and expands global strategic partnerships. His extensive experience in high-impact transactions and strategic licensing will strengthen SEED’s ability to accelerate breakthrough therapies in oncology, neurodegeneration, and immunology through our proprietary RITE3™ TPD platform. ”
Dr. Lan Huang, Co-Founder, Chairman at SEED Therapeutics
“ I am excited to join SEED at this transformative moment, working alongside an exceptional team of leaders and innovators. Together, we will advance SEED’s groundbreaking strategy, forge key alliances, and drive meaningful impact for patients and stakeholders worldwide. ”
Dr. Bill Desmarais, CFO & CBO at SEED Therapeutics
Why This Matters
The appointment of Dr. Bill Desmarais as CFO and CBO marks a strategic milestone for SEED Therapeutics as it transitions from discovery to clinical development. His leadership in major biotech transactions, including Momenta’s $6.5B acquisition by Johnson & Johnson, positions SEED to optimize its business development and financial strategies. With its RITE3™ TPD platform and first-in-class degraders, SEED is poised to transform treatments for oncology, neurodegeneration, immunology, and virology. The strengthening of SEED’s executive team supports its mission to tackle traditionally undruggable targets and deliver transformative therapies to patients worldwide.
